Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.44 |
| ▸ | NPY1R | P25929 | 7/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.42 |
| ▸ | NPY2R | P49146 | 4/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21062366 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL21062302 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL18072614 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL21062362 | 0.94 | CTSS (0.40) | NPY4RSIRT5 | |
| SCHEMBL19862037 | 0.94 | CTSS (0.40) | NPY4RSIRT5 | |
| SCHEMBL23192536 | 0.93 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL19862061 | 0.90 | CTSS (0.40) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL25469082 | 0.89 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL19862385 | 0.88 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL21096611 | 0.88 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009717-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-10633415-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-04-28 | — | — | US | disclosed |
| US-20180044378-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044378-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | NPY4R 135/4885NPY1R 140/4885NPY5R 246/4885 |
| US-10633415-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | NPY4R 135/4885NPY1R 140/4885NPY5R 246/4885 |
| US-20250009717-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY | TARDBP, NLN, PARK7 | NPY4R 2504/4885NPY1R 2413/4885NPY5R 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.